Clinical Trials Logo

Glioma of Brain clinical trials

View clinical trials related to Glioma of Brain.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT03102112 Enrolling by invitation - Glioma of Brain Clinical Trials

Noninvasively Predicting Gene Status of Glioma

NPGSOG
Start date: January 1, 2017
Phase: N/A
Study type: Observational

Malignant gliomas are the most common and deadly primary brain tumors in adults. The clinical outcome of patients with glioblastoma depends on key molecular genetic alteration. Specifically, Isocitrate Dehydrogenase Gene Mutation, an independent favorable prognostic factor, serve as diagnostic and prognostic markers of glioma. Thus, accurate grading of a glioma is fundamental in order to determine the treatment strategy. Amide proton transfer (APT) imaging is a noninvasive molecular MRI technique based on chemical exchange saturation transfer mechanism that detects endogenous mobile proteins and peptides in biological tissues. Preliminary studies have shown that APT-weighted (APTw) signal intensity could serve as a new imaging biomarker, by revealing significantly higher signal intensities in the high-grade gliomas compared with the low-grade gliomas. The purpose of this study was to investigate the value of amide proton transfer imaging (APT) in the noninvasive evaluation of isocitrate dehydrogenase (IDH) gene status in glioma.